

*Structural revision of sesbagrandidflorains
A and B, and synthesis and biological
evaluation of 6-methoxy-2-arylbenzofuran
derivatives*

**Noviany Noviany, Arash Samadi, Evan
L. Carpenter, Mostafa E. Abugrain,
Sutopo Hadi, Neny Purwitasari, Gitali
Indra, Arup Indra, et al.**

Journal of Natural Medicines

ISSN 1340-3443

Volume 75

Number 1

J Nat Med (2021) 75:66-75

DOI 10.1007/s11418-020-01445-2

Your article is protected by copyright and all rights are held exclusively by The Japanese Society of Pharmacognosy. This e-offprint is for personal use only and shall not be self-archived in electronic repositories. If you wish to self-archive your article, please use the accepted manuscript version for posting on your own website. You may further deposit the accepted manuscript version in any repository, provided it is only made publicly available 12 months after official publication or later and provided acknowledgement is given to the original source of publication and a link is inserted to the published article on Springer's website. The link must be accompanied by the following text: "The final publication is available at link.springer.com".



ORIGINAL PAPER

Structural revision of sesbagrindiflorains A and B, and synthesis and biological evaluation of 6-methoxy-2-arylbenzofuran derivatives

Noviany Noviany¹ · Arash Samadi² · Evan L. Carpenter² · Mostafa E. Abugrain² · Sutopo Hadi¹ · Neny Purwitasari³ · Gitali Indra² · Arup Indra² · Taifo Mahmud² Received: 28 June 2020 / Accepted: 11 August 2020 / Published online: 18 August 2020
© The Japanese Society of Pharmacognosy 2020

Abstract

Sesbagrindiflorains A (1) and B (2), isolated from the stem bark of the Indonesian fabaceous plant *Sesbania grandiflora*, were reported to be 6-methoxy-2-(2',3'-dihydroxy-5'-methoxyphenyl)-1-benzofuran-3-carbaldehyde and 6-hydroxy-2-(2',3'-dihydroxy-5'-methoxyphenyl)-1-benzofuran-3-carbaldehyde, respectively. However, based on reevaluation of their 1D and 2D NMR data, the chemical structures of 1 and 2 have been revised to 4-hydroxy-2-(4'-hydroxy-2'-methoxyphenyl)-6-methoxybenzofuran-3-carbaldehyde and 4-hydroxy-2-(4'-hydroxy-2'-hydroxyphenyl)-6-methoxybenzofuran-3-carbaldehyde, respectively. In addition, seven new derivatives of **1** have been synthesized from the natural product in good yields (65–93%). The chemical structures of the synthetic compounds—one diester (6), four ethers (7–10), one secondary amine (11), and one oxime (12)—were confirmed by MS and NMR analysis. Compound 6 exhibited moderate antibacterial activity against the plant pathogen *Rhodococcus fascians* with a MIC of 0.1 mg/mL. Compounds 8 and 12 demonstrated respectable cytotoxicity against A375 melanoma cancer cells line with the relative IC₅₀ values of 22.8 and 32.7 μM, respectively.

Keywords Antibacterial activity · Cytotoxicity · sesbagrindiflorain · *Sesbania grandiflora* · *Rhodococcus fascians*

Introduction

2-Arylbenzofurans are a group of natural products that exhibit various biological activities, e.g., α-glucosidase inhibitory activity [1], antioxidant [2–4], anti-inflammatory

[5], tyrosinase inhibitory activity [6], antitumor [7–11], and anti-Alzheimer's [12]. Members of this class of compounds have been identified in a wide variety of plants from the family of Moraceae (e.g., *Chlorophora regia* [3], *Artocarpus gomezianus* [1], *Morus alba* [4, 11, 13], *Morus cathayana* [10, 14], *Morus insignis* [15], *Morus notabilis* [6], *Morus wittorum* [5], *Morus yunannensis* [16]); Dipterocarpaceae (e.g., *Hopea megarawan* [8]); Lauraceae (e.g., *Nectandra purpurascens* [17]); Poaceae (e.g., *Oryza sativa* [2]); Melanthiaceae (e.g., *Schoenocaulon officinale* [18]); Fabaceae (e.g., *Erythrina burtii* [19], *Sophora tonkinensis* [20]); and Rutaceae (e.g., *Zanthoxylum capense* [9]). A subset of 2-arylbenzofuran natural products, the 2-arylbenzofuran-3-carbaldehydes (a.k.a. 3-formyl-2-arylbenzofurans), appear to be unique to certain plants from the family of Fabaceae (e.g., *Andira inermis* [21], *Erythrina variegata* [22], *Hedysarum multijugum* [23], *Medicago sativa* [24], and *Onobrychis ebenoides* [25, 26]), Iteaceae (*Itea ilicifolia* [27]), and Lamiaceae (e.g., *Salvia miltiorrhizae* [28]). Recently, a number of 2-arylbenzofuran-3-carbaldehydes (1–5) were isolated from the stem bark of an Indonesian fabaceous plant, *Sesbania grandiflora* (Fig. 1) [29, 30].


Noviany Noviany and Arash Samadi contributed equally.

Electronic supplementary material The online version of this article (<https://doi.org/10.1007/s11418-020-01445-2>) contains supplementary material, which is available to authorized users.

- ✉ Noviany Noviany
noviany@fmipa.unila.ac.id
- ✉ Taifo Mahmud
taifo.mahmud@oregonstate.edu

- ¹ Department of Chemistry, Faculty of Mathematics and Natural Sciences, University of Lampung, Bandar Lampung 35145, Indonesia
- ² Department of Pharmaceutical Sciences, Oregon State University, Corvallis, OR 97331-3507, USA
- ³ Department of Pharmacognosy and Phytochemistry, Faculty of Pharmacy, University of Airlangga, Surabaya 60286, Indonesia

Fig. 1 Chemical structures of natural 2-arylbenzofurans from *S. grandiflora* stem bark



Sesbagrandiflorain A (1) was the major constituent among the 2-arylbenzofuran-3-carbaldehydes isolated from *S. grandiflora* stem bark [29, 30]. Limited biological studies revealed that it has a moderate activity against certain cancer cell lines but did not show growth inhibitory activity against most bacteria [30]. Furthermore, compounds 1–5 have somewhat different cytotoxicity profiles [30], indicating that minor modifications of their chemical structures may directly affect their biological activities. Therefore, structural modifications of the natural products may lead to improved biological properties.

During the course of our semi-synthetic effort to produce derivatives of compound 1, we discovered that the reported chemical structure of 1 was incorrect. Here, we report structural revision of sesbagrandiflorain A (1) and its analog, sesbagrandiflorain B (2), as well as chemical derivatization of 1 and biological evaluation of the products against a number of bacterial strains, including the plant pathogen *Rhodococcus fascians*, and the melanoma cancer cells line A375.

Results and discussion

The chemical structure of sesbagrandiflorain A (1) was first reported to be 6-methoxy-2-(2',3'-dihydroxy-5'-methoxyphenyl)-1-benzofuran-3-carbaldehyde (Fig. 1)

[29]. However, upon careful reevaluation of the 1D and 2D NMR data for 1 (measured in both acetone-*d*₆ and CDCl₃), we concluded that the chemical structure of 1 is 4-hydroxy-2-(4'-hydroxy-2'-methoxyphenyl)-6-methoxybenzofuran-3-carbaldehyde (Fig. 1). In the revised structure, the positions of the hydroxy and methoxy groups in 1 have been reassigned; the A ring contains a hydroxy group at C-4 and a methoxy group at C-6; whereas, the C ring contains a hydroxy group at C-4' and a methoxy group at C-2'. HMBC correlations between the C-4 hydroxyl proton (δ_{H} 10.1 ppm) and C-4, C-5 and C-9 and between the C-6 methoxyl protons (δ_{H} 3.85 ppm) and C-6 (Fig. 3) support the reassignments of ring A; whereas, HMBC correlations between the C-2' methoxyl protons (δ_{H} 3.87 ppm) and C-2', and between the C-4' hydroxyl proton (δ_{H} 5.21 ppm) and C-4', C-5', and C-6' support the reassignments of ring C. In addition, NOESY correlations between the C-4 hydroxyl proton and H-5 (δ_{H} 6.47 ppm); the C-6 methoxyl protons and H-5; the C-2' methoxyl protons and the aldehyde proton (δ_{H} 9.82 ppm); as well as H-6' (δ_{H} 7.49 ppm) and the aldehyde proton further confirmed the chemical structure of 1. The revised chemical structure of sesbagrandiflorain A (1) is identical to a 2-arylbenzofuran-3-carbaldehyde found in the alfalfa plant *Medicago sativa* [24]. Comparisons of the ¹H NMR spectrum of 1 (taken in DMSO-*d*₆) with that reported in

the literature (Table S1) unambiguously confirmed the identity of 1.

Similarly, sesbagrandidlorain B (2) was first reported as 6-hydroxy-2-(2',3'-dihydroxy-5'-methoxyphenyl)-1-benzofuran-3-carbaldehyde [29]. Compound 2 differs from 1 only in the absence of a methyl group; and based on the reevaluation of the original 1D and 2D NMR data for 2, the chemical structure of 2 has been revised to be 4-hydroxy-2-(4'-hydroxy-2'-hydroxyphenyl)-6-methoxybenzofuran-3-carbaldehyde. Sesbagrandidlorain B is identical to ebenfuran II from *Onobrychis ebenoides* [7]. The ^1H NMR spectrum of 2 (taken in CD_3OD) is in a complete agreement with that reported in the literature (Table S1). From this point on, to maintain the priority of the previous discoveries, we will avoid using the name 'sesbagrandidlorain' for compound 1 and its derivatives.

Compound 1 was isolated from *S. grandiflora* stem bark in a good yield [29, 30]. This natural product contains a formyl and two free aromatic hydroxy groups, which were expected to be accessible to chemical derivatizations. Using this relatively abundant natural product as the starting material, we synthesized seven new 2-arylbenzofuran derivatives, ranging from a diester (6) to ethers (7–10), secondary amine (11), and oxime (12) in high yields (65–93%) (Fig. 2).

Compound 6 was synthesized by treating 1 with acetic anhydride in pyridine at room temperature for 24 h. The acetylation of OH-4 and OH-4' was confirmed by

HR-ESI-TOF-MS (399.10897 $[\text{M}+\text{H}]^+$) and ^1H NMR spectrum, in which two resonances at δ_{H} 2.41 and 2.33 ppm (3H each, *s*) for acetyl groups were present (Table 1). The ^{13}C NMR spectrum of 6 also showed resonances for two acetyl groups, δ_{C} 20.5 and 168.9 ppm for CH_3COO - at C-4 and δ_{C} 20.1 and 168.4 ppm for CH_3COO - at C-4' (Table 2). These assignments were confirmed by relatively weak but apparent 4JCH HMBC correlations between the acetyl protons at 2.41 ppm and C-4 (145.0 ppm) and between the acetyl protons at 2.33 ppm and C-4' (154.6) (Fig. 3).

Compound 7 was prepared by treating 1 with K_2CO_3 and CH_3I (2 mol. eq.) at 40 °C for 24 h. Direct comparisons of the ^1H and ^{13}C NMR spectra of 7 with those of 1 suggested that the methylation reaction took place regioselectively at the C-4' hydroxy group. This was further confirmed by the HMBC correlation between the CH_3O protons (3.93 ppm) with C-4' (163.5 ppm). Interestingly, addition of CH_3I up to 10 mol. eq. to the reaction mixture did not yield any permethylated product. It is postulated that the C-4 hydroxy group is less accessible than the C-4' hydroxy group, as the formyl moiety may form steric hindrance and/or hydrogen bonding with the C-4 hydroxy group.

Compound 8 was synthesized by treating 1 with K_2CO_3 and benzyl bromide at room temperature for 2 h. On the other hand, compounds 9 and 10 were synthesized by activating 1 with K_2CO_3 in DMF at room temperature for 30 min and then reacting it with prenyl bromide and geranyl bromide, respectively, for 3 h. Similar to compound 7, benzylation or prenylation of 1 only occurred at the C-4' hydroxy group as deduced by comparing their ^1H and ^{13}C NMR spectra with those of 1. Analysis of the 2D NMR data (HSQC, HMBC, and NOESY) for 9 also confirmed the regioselectivity of the ether formation (Fig. 3).

Compound 11 was synthesized by treating 1 with *n*-butylamine followed by reduction with NaBH_4 . The ^1H NMR of 11 exhibited resonances at δ_{H} 1.60 (2H, *q*, $J=7.5$ Hz), 1.41 (2H, *m*), and 0.95 (3H, *t*, $J=7.3$ Hz) ppm, attributed to alkyl protons, along with two sets of methylene protons attached to a nitrogen atom at δ_{H} 2.78 (2H, *t*, $J=7.3$ Hz) and 3.84 (*s*) ppm. The ^{13}C NMR spectrum of 11 showed all of the carbon resonances expected for 11 (Table 2).

The synthesis of 12 was carried out by treating 1 with BnONH_3Cl in pyridine at room temperature for 24 h. The product was confirmed by NMR and HRESIMS. The positive-ion mode HRESIMS of 12 displayed a characteristic molecular ion peak $[\text{M}+\text{H}]^+$ at m/z 420.14569 (calcd for $\text{C}_{24}\text{H}_{21}\text{NO}_6^+$, 420.14416), establishing the molecular formula of 12 as $\text{C}_{24}\text{H}_{20}\text{NO}_6$ with 15 degrees of unsaturation. This is consistent with the expected additional one degree of unsaturation from the $\text{C}=\text{N}$ moiety in 12. The ^1H NMR spectrum of 12 revealed the presence of an imine proton at δ_{H} 8.16 (1H, *s*), methylene protons at δ_{H} 5.23 (2H, *s*), and monosubstituted benzene protons at δ_{H} 7.47 (2H, *t*,




Fig. 2 Chemical structures of compound 1 derivatives

Table 1 ^1H NMR data for compounds 1 and 6–12

Position	1 ^a $\delta_{\text{H}}; J^{\text{c}}$	6 ^b $\delta_{\text{H}}; J$	7 ^c $\delta_{\text{H}}; J$	8 ^d $\delta_{\text{H}}; J$	9 ^b $\delta_{\text{H}}; J$	10 ^b $\delta_{\text{H}}; J$	11 ^a $\delta_{\text{H}}; J$	12 ^d $\delta_{\text{H}}; J$
HO-(4)	10.1 (s)	–	10.18 (s)	10.21 (s)	10.20 (s)	10.20 (s)	–	10.37 (s)
5	6.47 (d, 2.0)	6.74 (d, 2.0)	6.47 (d, 2.0)	6.37 (s)	6.37 (d, 2.0)	6.36 (d, 2.0)	6.39 (d, 2.0)	6.27 (d, 2.1)
7	6.60 (m)	7.16 (d, 2.0)	6.61 (s)	6.71 (s)	6.70 (d, 2.0)	6.70 (d, 2.0)	6.55 (d, 2.0)	6.60 (d, 2.1)
MeO-(6)	3.85 (s)	3.93 (s)	3.85 (s)	3.86 (s)	3.86 (s)	3.86 (s)	3.83 (s)	3.83 (s)
10	9.82 (s)	9.82 (s)	9.82 (s)	9.86 (s)	9.85 (s)	9.85 (s)	3.84 (s)	8.16 (s)
MeO-(2')	3.87 (s)	3.91 (s)	3.88 (s)	3.95 (s)	3.94 (s)	3.94 (s)	3.85 (s)	3.82 (s)
3'	6.59 (m)	7.10 (d, 2.0)	6.62 (s)	6.94 (s)	6.82 (d, 2.0)	6.82 (d, 2.2)	6.57 (d, 2.0)	6.67 (d, 2.1)
HO-(4')	5.21 (s)	–	–	–	–	–	n.o	9.0
5'	6.60 (m)	7.00 (dd, 8.5, 2.0)	6.67 (d, 8.4)	6.89 (d, 8.4)	6.79 (dd, 8.5, 2.0)	6.79 (dd, 8.5, 2.2)	6.54 (dd, 9.0, 2.0)	6.62 (dd, 8.4, 2.1)
6'	7.49 (d, 8.9)	7.71 (d, 8.5)	7.55 (d, 8.4)	7.68 (d, 8.4)	7.65 (d, 8.5)	7.65 (d, 8.5)	7.32 (d, 9.0)	7.36 (d, 8.4)
CH ₂ O	–	–	–	5.30 (s)	–	–	–	5.23 (s)
MeO-(4')	–	–	3.93 (s)	–	–	–	–	–
MeCOO-(4)	–	2.41 (s)	–	–	–	–	–	–
MeCOO-(4')	–	2.33 (s)	–	–	–	–	–	–
1''	–	–	–	–	4.73 (m)	4.76 (d, 6.3)	2.78 (t, 7.3)	–
2''	–	–	–	7.46 (t, 7.7)	5.54 (t, 6.5)	5.54 (m)	1.60 (q, 7.5)	7.47 (t, 7.7)
3''	–	–	–	7.56 (t, 7.7)	–	–	1.41 (m)	7.41 (t, 7.7)
4''	–	–	–	7.39 (t, 7.7)	1.81 (s)	2.18 (m)	0.95 (t, 7.3)	7.35 (t, 7.7)
5''	–	–	–	7.56 (t, 7.7)	1.82 (s)	2.13 (m)	–	7.41 (t, 7.7)
6''	–	–	–	7.46 (t, 7.7)	–	5.14 (m)	–	7.47 (t, 7.7)
8''	–	–	–	–	–	1.67 (s)	–	–
9''	–	–	–	–	–	1.63 (s)	–	–
10''	–	–	–	–	–	1.82 (s)	–	–

s singlet, d doublet, dd doublet of doublets, dt doublet of triplets, t triplet, q quartet, m multiplet, coupling constants (apparent splittings) are reported as numerical values in Hz, n.o. not observed

^a ^1H NMR (500 MHz) measured in CDCl_3

^b ^1H NMR (500 MHz) measured in acetone- d_6

^c ^1H NMR (700 MHz) measured in CDCl_3

^d ^1H NMR (700 MHz) measured in acetone- d_6

^eMultiplicity of signals is given in parentheses

$J=7.7$ Hz), 7.41 (2H, t, $J=7.7$ Hz), and 7.35 ppm (1H, t, $J=7.7$ Hz), confirming the presence of an *O*-benzyl oxime moiety in 12. This was also supported by its ^{13}C NMR data (Table 2).

Compounds 6–12 were evaluated for their antibacterial activity against *Staphylococcus aureus*, *Bacillus subtilis*, *Mycobacterium smegmatis*, *Pseudomonas aeruginosa*, *Escherichia coli* and *Rhodococcus fascians* using an agar diffusion assay. The results showed that only compound 6 had moderate antibacterial activity against the plant pathogen *R. fascians*, with a MIC of 0.1 mg/mL (Fig. 4a, b). None of the other compounds including 1 were active against the tested bacteria. The presence of acetyl groups at C-2' and C-3' in the B-ring of 6 may play a role in the growth inhibitory activity and/or in the uptake of the compound into *R. fascians*.

In addition, the compounds were also tested for their cytotoxicity against A375 melanoma cancer cells line (Fig. 4c). The results showed that compounds 8 and 12 showed better cytotoxicity than 1 and the other derivatives against the cancer cell line with the relative IC_{50} values of 22.80 and 32.73 μM , respectively (Figs. 4c and 3d). Compounds 8 and 12 contain an additional benzene ring in their structures, which may contribute to the growth inhibitory activity against A375 melanoma cancer cells. Further investigations on the anti-Rhodococcal activity of compound 6 and the cancer cell growth inhibitory activity of compounds 8 and 12 are warranted to understand the mechanisms underlying their antibacterial activity or cytotoxicity and to develop more active antibacterial or anticancer agents.

Table 2 ^{13}C NMR data for compounds 1 and 6–12

Position	1 ^a δ_{C}	6 ^b δ_{C}	7 ^c δ_{C}	8 ^d δ_{C}	9 ^b δ_{C}	10 ^b δ_{C}	11 ^c δ_{C}	12 ^d δ_{C}
2	162.6	162.7	162.8	163.0	163.2	163.2	152.3	154.6
3	119.0	118.2	119.0	118.7	118.6	118.6	114.2	109.4
4	151.9	145.0	152.0	152.0	151.9	152.0	145.7	151.7
5	98.3	107.2	98.2	98.1	98.1	98.1	97.3	97.6
6	160.9	159.4	160.9	161.2	161.2	161.2	157.7	160.6
7	88.2	93.7	88.2	87.7	87.6	87.7	87.5	87.4
8	156.6	156.7	156.6	156.6	156.6	156.6	156.7	156.9
9	107.2	111.9	107.3	107.8	106.9	106.9	107.0	107.4
MeO-(6)	55.8	55.6	55.8	55.5	55.4	55.5	55.7	55.1
10	191.1	184.8	191.1	190.1	190.2	190.1	44.5	145.5
1'	110.3	114.5	110.3	109.9	109.5	109.6	111.9	109.8
2'	158.9	158.7	158.7	159.0	158.9	158.9	158.4	158.7
3'	99.7	106.4	99.2	99.9	99.5	99.6	99.5	99.8
4'	159.5	154.6	163.5	163.1	163.2	163.2	159.7	160.9
5'	108.1	114.2	105.6	106.9	106.8	106.9	107.5	107.8
6'	132.9	132.5	132.8	132.8	132.7	132.7	132.1	132.3
MeO-(2')	55.9	55.7	55.8	55.2	55.2	55.2	55.7	55.0
CH ₂ O	–	–	–	70.1	–	–	–	76.1
MeO-(4')	–	–	55.6	–	–	–	–	–
MeCOO-(4)	–	20.5	–	–	–	–	–	–
MeCOO-(4')	–	20.1	–	–	–	–	–	–
MeCOO-(4)	–	168.9	–	–	–	–	–	–
MeCOO-(4')	–	168.4	–	–	–	–	–	–
1''	–	–	–	136.8	65.0	65.1	48.5	137.1
2''	–	–	–	127.7	119.6	119.6	31.4	128.3
3''	–	–	–	128.5	137.8	141.1	20.3	128.4
4''	–	–	–	128.0	17.3	39.3	13.8	128.1
5''	–	–	–	128.5	24.9	26.2	–	128.4
6''	–	–	–	127.7	–	123.8	–	128.3
7''	–	–	–	–	–	131.3	–	–
8''	–	–	–	–	–	24.9	–	–
9''	–	–	–	–	–	16.8	–	–
10''	–	–	–	–	–	15.8	–	–

^a ^{13}C NMR (125 MHz) measured in CDCl_3 ^b ^{13}C NMR (125 MHz) measured in acetone- d_6 ^c ^{13}C NMR (176 MHz) measured in CDCl_3 ^d ^{13}C NMR (176 MHz) measured in acetone- d_6

Experimental section

General experimental procedures

All of the solvents, reagents, and chemicals used in this study were purchased from Aldrich Chemical (Saint Louis, MO, USA) and Merck AG (Saint Louis, MO, USA). Thin-layer chromatography (TLC) was conducted on pre-coated silica gel 60 GF₂₅₄ plates (Merck, Darmstadt, Germany) with an absorbent thickness of 0.25 mm sprayed with $\text{Ce}(\text{SO}_4)_2$ solution for spot visualization. Preparative TLC was performed

on square glass plates with a side length of 0.2 m coated with 0.5-mm Kieselgel F₂₅₄ (Merck), which were air dried and used without prior activation. Column chromatography (CC) was performed on silica gel (Kieselgel 60, 70–230 mesh ASTM; Merck). HPLC was performed using a Shimadzu dual LC-20AD solvent delivery system with a Shimadzu SPD-M20A UV/vis photodiode array detector. Nuclear magnetic resonance (^1H NMR and ^{13}C NMR) spectra were recorded in acetone- d_6 or CDCl_3 with tetramethylsilane as an internal standard on a Bruker Avance III 700-MHz spectrometer equipped with a 5-mm ^{13}C cryogenic probe or a




Fig. 3 HMBC and NOESY correlations of compound 1 and some of its derivatives

Bruker 500-MHz spectrometer. High-resolution ESI mass spectrometry was performed in positive-ion mode on a 6230 TOF mass spectrometer (Agilent Technologies, Santa Clara, CA).

Isolation of compound 1 from the stem bark of *S. grandiflora*

Compound 1 was isolated from the stem bark of *S. grandiflora* using the method described in our previous report [29]. The identity of the compound was confirmed by NMR and MS.

Synthesis of compound 1 derivatives

Synthesis of 2-(4-acetoxy-2-methoxyphenyl)-3-formyl-6-methoxybenzofuran-4-yl acetate (6). Compound 1 (5 mg, 0.0159 mmol) was dissolved in acetic anhydride (0.44 mL) and pyridine (0.44 mL). The solution was stirred at room temperature for 24 h. The reaction completion was confirmed by TLC (CH_2Cl_2 -MeOH = 9:1). The reaction mixture was then poured into ice water and the precipitate was collected by filtration. The precipitate was subjected to SiO_2 flash column chromatography eluted with CH_2Cl_2 -MeOH (40:1) to give compound 6 as a colorless oil (5.9 mg, 93%).




Fig. 4 Antibacterial activity and cytotoxicity of compound 1 derivatives. **a** Agar-based disc diffusion assay of 1, 6, 8, 9, 12 against *R. fascians*; **b** Micro-dilution assay of 6 against *R. fascians*; Compound 6: 10–0.0001 mg/mL; Apramycin (Apr): 0.0001 mg/mL; NC (no compound or negative control); SL (solvent only); **c, d** Dose–response curves for the effect of compounds 6–12 on survival of A375 human

metastatic melanoma cells following 48 h of treatment. **c** Results from the primary screen and **d** validation of hit compounds. Data represent the mean \pm standard deviation for triplicate values from one experiment **c** or two independent experiments performed in triplicate **d**

ESI-TOF-MS m/z 399.10897 $[M+H]^+$, calculated for $C_{21}H_{18}O_8$ for 399.10744; 1H and ^{13}C NMR spectral data (acetone- d_6): see Tables 1 and 2, respectively.

Synthesis of 2-(2,4-dimethoxyphenyl)-4-hydroxy-6-methoxybenzofuran-3-carbaldehyde (7). Compound 1 (5 mg, 0.0159 mmol) was dissolved in DMF (0.03 mL) and stirred with K_2CO_3 (10 eq, 0.159 mmol, 22 mg) and CH_3I (10 eq, 0.159 mmol, 0.01 mL) at 40 °C for 24 h. The reaction completion was confirmed by TLC (CH_2Cl_2 –MeOH = 9:1). The mixture was diluted with EtOAc, and washed with water and brine. The EtOAc fraction was dried with Na_2SO_4 and the volatiles were removed *in vacuo*. The resulting pale yellow oil was purified by flash chromatography (CH_2Cl_2 –MeOH = 95:5) to yield 7 as white crystals (4.1 mg, 78%).

ESI-TOF-MS m/z 329.10340 $[M+H]^+$, calculated for $C_{18}H_{16}O_6$ for 329.10196. 1H and ^{13}C NMR spectral data ($CDCl_3$): see Tables 1 and 2, respectively.

Synthesis of 2-(4-(benzyloxy)-2-methoxyphenyl)-4-hydroxy-6-methoxybenzofuran-3-carbaldehyde (8). Compound 1 (1.0 eq, 5.00 mg, 0.0159 mmol) was dissolved in DMF (0.03 mL). Benzyl bromide (2.0 eq, 0.01 mL, 0.0318 mmol)

and K_2CO_3 (7 mg, 0.047 mmol) were added to the solution. The yellow mixture was stirred at room temperature for 2 h, poured into a solution of Et_2O – H_2O (1:1), and stirred for 10 min. The ethereal layer was separated. The aqueous layer was extracted with Et_2O . The combined extract was washed with H_2O and brine. The organic layer was dried over anhydrous Na_2SO_4 , filtered, and concentrated to dryness. The resulting pale yellow oil was purified by flash column chromatography (hexane–acetone = 9:1) to yield product 8 as a pale yellow solid (5.2 mg, 80%).

ESI-TOF-MS m/z 405.13463 $[M+H]^+$, calculated for $C_{24}H_{20}O_6$ for 405.13463. 1H and ^{13}C NMR spectral data (acetone- d_6): see Tables 1 and 2, respectively.

Synthesis of 4-hydroxy-6-methoxy-2-(2-methoxy-4-((3-methylbut-2-en-1-yl)oxy)phenyl)benzofuran-3-carbaldehyde (9). To a solution of compound 1 (5 mg, 1.0 eq, 0.0159 mmol) in DMF (0.2 mL) was added K_2CO_3 (9 mg, 0.063 mmol), and the reaction mixture was stirred for 30 min at rt. Subsequently, prenyl bromide (4 μ L, 0.0318 mmol) was added to the reaction mixture and stirred for another 3 h until complete consumption of the starting material as judged by TLC. The reaction was then

quenched with potassium phosphate buffer pH 7.0 and extracted with EtOAc twice. The EtOAc layer was dried over anhydrous Na_2SO_4 , then the organic solvent was dried *in vacuo*. The extract was subjected to SiO_2 column chromatography using hexane–acetone (9:1) as mobile phase. Fractions containing the product were pooled and dried under vacuum to give the title compound 9 as a pale yellow solid (4.0 mg, 65%).

ESI-TOF-MS m/z 383.15035 $[\text{M} + \text{H}]^+$, calculated for $\text{C}_{22}\text{H}_{22}\text{O}_6$ for 383.15035. ^1H NMR (acetone- d_6) and ^{13}C NMR spectral data (acetone- d_6): see Tables 1 and 2, respectively.

Synthesis of (Z)-2-(4-((3,7-dimethylocta-2,6-dien-1-yl)oxy)-2-methoxyphenyl)-4-hydroxy-6-methoxybenzofuran-3-carbaldehyde (10). To a solution of compound 1 (5 mg, 1.0 eq, 0.0159 mmol) in DMF (0.2 mL) was added K_2CO_3 (9 mg, 0.066 mmol), and the reaction mixture was stirred for 30 min at rt. Subsequently, geranyl bromide (6 μL , 0.0318 mmol) was added to the reaction mixture and stirred for another 3 h until complete consumption of the starting material as judged by TLC. The reaction was then quenched with potassium phosphate buffer pH 7.0 and extracted with EtOAc twice. The EtOAc layer was dried over anhydrous Na_2SO_4 ; then the organic solvent was dried *in vacuo*. The extract was subjected to silica gel column chromatography using hexane–acetone (9:1) as mobile phase. Fractions containing the product were pooled and dried under vacuum to give the title compound 10 as a pale yellow solid (4.8 mg, 66%).

ESI-TOF-MS m/z 451.21298 $[\text{M} + \text{H}]^+$, calculated for $\text{C}_{27}\text{H}_{30}\text{O}_6$ for 451.21152. ^1H NMR (acetone- d_6) and ^{13}C NMR spectral data (acetone- d_6): see Tables 1 and 2, respectively.

Synthesis of 2-(4-hydroxy-2-methoxyphenyl)-6-methoxy-3-((propylamino)methyl)benzofuran-4-ol (11). A suspension of *n*-butyl amine (0.02 mL, 1.1 eq, 0.0175 mmol) in pyridine (0.2 mL) was added to compound 1 (5 mg, 0.0159 mmol), then stirred at room temperature for 24 h. TLC (CH_2Cl_2 –MeOH = 10:1) indicated reaction complete. The solvent was evaporated *in vacuo*. The reaction was diluted with EtOAc, washed with 0.1-M HCl, water, saturated NaHCO_3 , water, brine and dried over Na_2SO_4 , filtered and volatiles removed *in vacuo*. The resulting product (5.6 mg, 0.0151 mmol) was added to MeOH (0.03 mL) and the resulting mixture was stirred at rt, then NaBH_4 (2.0 eq, 0.04 mmol, 1 mg) was added at 0 °C, and stirring was continued overnight at rt. The resulting mixture was acidified with 2 N HCl and then neutralized with saturated aqueous NaHCO_3 solution to yield a white solution. The solution was extracted with EtOAc. The organic layer was washed with brine, dried over Na_2SO_4 , and concentrated *in vacuo* to yield product 11 as brown oil (4.5 mg, 80%, 2 step).

ESI-TOF-MS m/z 372.18222 $[\text{M} + \text{H}]^+$, calculated for $\text{C}_{21}\text{H}_{25}\text{NO}_5$ for 372.18222. ^1H and ^{13}C NMR spectral data (CDCl_3): see Tables 1 and 2, respectively.

Synthesis of (E)-4-hydroxy-2-(4-hydroxy-2-methoxyphenyl)-6-methoxybenzofuran-3-carbaldehyde O-benzyl oxime (12). A suspension of BnONH_3Cl (3 mg, 1.1 eq, 0.0159 mmol) in pyridine (0.2 mL) was added to compound 1 (5 mg, 0.0159 mmol), then stirred at room temperature for 24 h. The solvent was evaporated *in vacuo* and the reaction mixture was diluted with EtOAc, consecutively washed with 0.1-M HCl, saturated NaHCO_3 , water, and brine. The organic fraction was then dried over Na_2SO_4 , filtered, and the solvent was evaporated *in vacuo* to afford product 12 as white solid (4.6 mg, 70%).

ESI-TOF-MS m/z 420.14569 $[\text{M} + \text{H}]^+$, calculated for $\text{C}_{24}\text{H}_{21}\text{NO}_6$ for 420.14416. ^1H and ^{13}C NMR spectral data (acetone- d_6): see Tables 1 and 2, respectively.

Antibacterial activity assay

Agar-based disc diffusion assay was used to test the activity of all the tested derivative compounds. Five different bacteria, *S. aureus* ATCC 12,600, *B. subtilis* ATCC 6051, *P. aeruginosa* ATCC 9721, *M. smegmatis* ATCC 14,468, and *E. coli* ATCC 11,775 were used. The EtOAc extract was dissolved in MeOH to a concentration of 10 mg/mL. The positive control for this experiment was either ampicillin (for *S. aureus*, *B. subtilis*, *P. aeruginosa*, and *E. coli*) or apramycin (for *M. smegmatis*). All the tested compounds and the positive control (10 μL each) were loaded onto sterile diffusion discs and left to dry for 20 min. For *S. aureus*, *B. subtilis*, *P. aeruginosa*, and *M. smegmatis*, the agar plates were prepared by adding a layer of bacterial infused YMG soft agar to an YMG plate and left to solidify. The bacterial infused YMG soft agar was prepared by growing each of the bacteria in separate 15-mL falcon tubes with liquid YMG medium for two days and mixed it with warm YMG agar. The paper discs, impregnated with the compound and the positive control, were placed onto each plates using antiseptic techniques. All plates were incubated for 24 h at 30 °C. For *E. coli*, all procedures mentioned above were done using Luria–Bertani (LB) medium instead of YMG. In addition, the *E. coli* plates and liquid cultures were incubated at 37 °C. After 24 h of incubation, the plates were stained with MTT (1 mg/mL in deionized water) to enhance the contrast of the inhibition zones to the bacterial growth.

Antibacterial activity of compound 6 against *Rhodococcus fascians* was determined by both agar-based disc diffusion and micro-dilution assays. *R. fascians* from a – 80 °C stock was streaked on MM nutrient agar medium [mannitol (10 g), casein (4 g), peptone (4 g), NH_4Cl (1 g), MgSO_4 (0.3 g), NaCl (0.2 g), yeast extract (3 g), and KH_2PO_4

(0.5 g)] and grown at 30 °C for 3 days. A colony was transferred to MM nutrient broth and incubated at 30 °C for 3 days. Turbidity of the inoculum was measured to a proper density at 600 nm–0.1. For plate preparation, inoculum (500 µL) was mixed thoroughly with warm nutrient agar (50 mL) and poured to 25-mL plates. The agar plate was let to solidify and dry for 30 min before assay. Sterile blank paper disks (Becton–Dickinson) were impregnated with the compound (10 mg/mL, 20 µL) and dried at rt. The disks were placed onto inoculated agar plates and incubated at 30 °C for 3 days. Micro-dilution assays were performed in a 96-well plate. Compound 6 was serially diluted and added to the bacterial suspension at final concentrations of 10, 1, 0.1, 0.01, 0.001 and 0.0001 mg/mL. After incubation at 30 °C for 3 days, 0.25% MTT developing dye (50 µL) was added. Control assays were done using the same protocol using apramycin or MeOH.

Cytotoxicity assay

Cell culture

A375 (ATCC: CRL-1619, Manassas, VA, USA) human metastatic melanoma cells were cultured in complete growth medium consisting of DMEM (Gibco, Waltham, MA, USA) supplemented with 10% FBS (Atlanta Biologicals, Flowery Branch, GA, USA) and 1% penicillin–streptomycin (Gibco). Cells were cultured in 75-cm² flasks (Greiner Bio-One, Kremsmünster, Austria), incubated in a humidified environment at 37 °C with 5% CO₂, and were kept below 20 passages.

Dose–response assays

Cells were seeded at 7000 cells/well into white, opaque 96-well plates (Greiner Bio-One) and incubated for 24 h prior to compound treatment. Wells on the outer edge of the plate were excluded for these assays and filled with PBS. Compounds dissolved in DMSO were then added to construct a 10-point dose–response curve in triplicate using a half-log serial dilution starting at 100 µM. For each serial dilution, a concurrent vehicle control serial dilution was performed in triplicate on the same plate. Treated cells were then allowed to incubate for 48 h. Afterwards, the percentage of viable cells was determined using the CellTiter-Glo Assay (Promega, Madison, WI, USA) with luminescence output measured using a Synergy4 (Biotek, Winooski, VT, USA) plate reader. Dose–response curves were fit to either a 3-parameter IC₅₀ model (primary screen) or a 4-parameter IC₅₀ model (hit validation) using GraphPad Prism 5 (GraphPad Software, San Diego, CA, USA).

Acknowledgements The authors thank the Directorate of Research and Community Services, Directorate General of Higher Education, The Ministry of Research, Technology and Higher Education, Republic of Indonesia for providing funds for this project through PSN Grant 2017-2019 (No. 860/UN26.21/PN/2019), PDUPT Grant 2019 (No. 856/UN26.21/PN/2019) and World Class Professor Program-Scheme B 2018 (No.123.44/D2.3/KP/2018). Work at Oregon State University was funded by the National Institute of Food and Agriculture of the U.S. Department of Agriculture under Award Number 2014-51181-22384 and the National Center for Complementary & Integrative Health of the National Institutes of Health under Award Number T32AT010131. The content is solely the responsibility of the authors and does not necessarily represent the official views of the U.S. Department of Agriculture and/or the National Institutes of Health. We acknowledge the support of the Oregon State University NMR Facility funded in part by the National Institutes of Health, HEI Grant 1S10OD018518, and by the M. J. Murdock Charitable Trust grant #2014162.

References

- Nuntawong P, Kongkatitham V, Likhitwitayawuid K, Mekboonsonglarp W, Sukrong S, Tanasupawat S, Sritularak B (2019) New 2-arylbenzofurans from the root bark of *Artocarpus gomezianus* and their alpha-glucosidase inhibitory activity. *Nat Prod Res* 33:1436–1441
- Han SJ, Ryu SN, Kang SS (2004) A new 2-arylbenzofuran with antioxidant activity from the black colored rice (*Oryza sativa* L.) bran. *Chem Pharm Bull* 52:1365–1366
- Kykykyku JO, Kusari S, Adosraku RK, Zuhlke S, Spiteller M (2016) Prenylated 2-arylbenzofuran derivatives with potent antioxidant properties from *Chlorophora regia* (Moraceae). *Fitoterapia* 108:41–47
- Paudel P, Seong SH, Wagle A, Min BS, Jung HA, Choi JS (2020) Antioxidant and anti-browning property of 2-arylbenzofuran derivatives from *Morus alba* Linn root bark. *Food Chem* 309:125739
- Tan YX, Gong T, Liu C, Chen RY, Yu DQ (2010) Five new 2-arylbenzofuran derivatives from *Morus wittiorum*. *Chem Pharm Bull* 58:579–581
- Hu X, Wang M, Yan GR, Yu MH, Wang HY, Hou AJ (2012) 2-Arylbenzofuran and tyrosinase inhibitory constituents of *Morus notabilis*. *J Asian Nat Prod Res* 14:1103–1108
- Katsanou ES, Halabalaki M, Aligiannis N, Mitakou S, Skaltsounis AL, Alexi X, Pratsinis H, Alexis MN (2007) Cytotoxic effects of 2-arylbenzofuran phytoestrogens on human cancer cells: modulation by adrenal and gonadal steroids. *J Steroid Biochem Mol Biol* 104:228–236
- Juliawaty LD, Sahidin HEH, Achmad SA, Syah YM, Latip J, Said IM (2009) A 2-arylbenzofuran derivative from *Hopea mengarawan*. *Nat Prod Commun* 4:947–950
- Mansoor TA, Borralho PM, Luo X, Mulhovo S, Rodrigues CM, Ferreira MJ (2013) Apoptosis inducing activity of benzophenanthridine-type alkaloids and 2-arylbenzofuran neolignans in HCT116 colon carcinoma cells. *Phytomedicine* 20:923–929
- Ni G, Zhang QJ, Zheng ZF, Chen RY, Yu DQ (2009) 2-Arylbenzofuran Derivatives from *Morus cathayana*. *J Nat Prod* 72:966–968
- Yang Y, Gong T, Liu C, Chen RY (2010) Four new 2-arylbenzofuran derivatives from leaves of *Morus alba* L. *Chem Pharm Bull* 58:257–260
- Rizzo S, Tarozzi A, Bartolini M, Da Costa G, Bisi A, Gobbi S, Belluti F, Ligresti A, Allara M, Monti JP, Andrisano V, Di Marzo V, Hrelia P, Rampa A (2012) 2-Arylbenzofuran-based molecules as multipotent Alzheimer's disease modifying agents. *Eur J Med Chem* 58:519–532

13. Nomura T, Fukai T (1981) Mulberrofuran B, a new isoprenoid 2-arylbenzofuran from the root bark of the cultivated mulberry tree. *Planta Med* 42:197–199
14. Shi YQ, Nomura T, Fukai T (2007) A new 2-arylbenzofuran from the root bark of Chinese *Morus cathayana*. *Fitoterapia* 78:617–618
15. Basnet P, Kadota S, Terashima S, Shimizu M, NT (1993) Two new 2-arylbenzofuran derivatives from hypoglycemic activity-bearing fractions of *Morus insignis*. *Chem Pharm Bull* 41:1238–1243
16. Hu X, Wu JW, Wang M, Yu MH, Zhao QS, Wang HY, Hou AJ (2012) 2-Arylbenzofuran, flavonoid, and tyrosinase inhibitory constituents of *Morus yunnanensis*. *J Nat Prod* 75:82–87
17. Rios-Motta J, Avella E (2010) 2-Arylbenzofuran neolignans from the bark of *Nectandra purpurascens* (Lauraceae). *Nat Prod Commun* 5:1063–1066
18. Kanchanapoom T, Suga K, Kasai R, Yamasaki K, Kamel MS, Mohamed MH (2002) Stilbene and 2-arylbenzofuran glucosides from the rhizomes of *Schoenocaulon officinale*. *Chem Pharm Bull* 50:863–865
19. Yenesew A, Midiwo JO, Guchu SM, Heydenreich M, Peter MG (2002) Three isoflav-3-enes and a 2-arylbenzofuran from the root bark of *Erythrina burtii*. *Phytochemistry* 59:337–341
20. Luo G, Yang Y, Zhou M, Ye Q, Liu Y, Gu J, Zhang G, Luo Y (2014) Novel 2-arylbenzofuran dimers and polyisoprenylated flavanones from *Sophora tonkinensis*. *Fitoterapia* 99:21–27
21. Kraft C, Jenett-Siems K, Siems K, Solis PN, Gupta MP, Bienzle U, Eich E (2001) Andinermals A-C, antiplasmodial constituents from *Andira inermis*. *Phytochemistry* 58:769–774
22. Tanaka H, Hirata M, Etoh H, Sako M, Sato M, Murata J, Murata H, Darnaedi D, Fukai T (2004) Six new constituents from the roots of *Erythrina variegata*. *Chem Biodivers* 1:1101–1108
23. Wang W, Zhao YY, Wang B, Liang H, Tu GZ, Chen HB (2007) Two new arylbenzofurans from the roots of *Hedysarum multi-jugum*. *J Asian Nat Prod Res* 9:19–22
24. Wang S, Zhang G, Guan J, Zhu L, Chen L, Pan C, Li P, Li L (2009) A new arylbenzofuran from the aerial parts of alfalfa. *J Nat Med* 63:189–191
25. Halabalaki M, Alexi X, Aligiannis N, Alexis MN, Skaltsounis AL (2008) Ebenfurans IV-VIII from *Onobrychis ebenoides*: evidence that C-prenylation is the key determinant of the cytotoxicity of 3-formyl-2-arylbenzofurans. *J Nat Prod* 71:1934–1937
26. Halabalaki M, Aligiannis N, Papoutsis Z, Mitakou S, Moutsatsou P, Sekeris C, Skaltsounis AL (2000) Three new arylobenzofurans from *Onobrychis ebenoides* and evaluation of their binding affinity for the estrogen receptor. *J Nat Prod* 63:1672–1674
27. Luo G, Zhou M, Liu Y, Ye Q, Gu J, Huang T, Zhang G, Luo Y (2014) 3-Formyl-2-arylbenzofurans from the aerial parts of *Itea ilicifolia*. *Phytochem Lett* 10:19–22
28. Chang JY, Chang CY, Kuo CC, Chen LT, Wein YS, Kuo YH (2004) Salvinal, a novel microtubule inhibitor isolated from *Salvia miltiorrhizae* Bunge (Danshen), with antimitotic activity in multidrug-sensitive and -resistant human tumor cells. *Mol Pharmacol* 65:77–84
29. Noviany N, Nurhidayat A, Hadi S, Suhartati T, Aziz M, Purwitasari N, Subasman I (2018) Sesbigrandiflorain A and B: isolation of two new 2-arylbenzofurans from the stem bark of *Sesbania grandiflora*. *Nat Prod Res* 32:2558–2564
30. Noviany N, Samadi A, Yuliyani N, Hadi S, Aziz M, Purwitasari N, Mohamad S, Ismail NN, Gable KP, Mahmud T (2020) Structure characterization and biological activity of 2-arylbenzofurans from an Indonesian plant, *Sesbania grandiflora* (L.) Pers. *Phytochem Lett* 35:211–215

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.